Addressing Manufacturing Challenges for Commercialization of iPSC-Based Therapies.

导出 LinkOut

翻译打印收藏纠错

作者： Mehdi,Dashtban ^[1] ; Krishna Morgan,Panchalingam ^[1] ; Mehdi,Shafa ^[1] ; Behnam,Ahmadian Baghbaderani ^[2]

作者单位： Cell Therapy Process Department, Lonza Houston, Inc., Houston, TX, USA. ^[1] Cell Therapy Process Department, Lonza Houston, Inc., Houston, TX, USA. behnam.ahmadianbaghbaderani@lonza.com. ^[2]

关键词 3D computer-controlled bioreactors Cell therapy Commercialization Induced pluripotent stem cells Process development cGMP

主题词生物医学技术(Biomedical Technology);商业化(Commodification);人类(Humans);诱导多能干细胞(Induced Pluripotent Stem Cells);诊疗准则(主题)(Practice Guidelines as Topic);再生医学(Regenerative Medicine)

DOI 10.1007/7651_2020_288

PMID 32430594

发布时间 2021-06-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Methods in molecular biology (Clifton, N.J.)

2021年2286卷

179-198页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Addressing Manufacturing Challenges for Commercialization of iPSC-Based Therapies.

Methods in molecular biology (Clifton, N.J.)

相似文献

Methods in molecular biology (Clifton, N.J.)

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Addressing Manufacturing Challenges for Commercialization of iPSC-Based Therapies.

Methods in molecular biology (Clifton, N.J.)

相似文献

Methods in molecular biology (Clifton, N.J.)

相关期刊

检索历史清除